Bunse L, Lindner K, Wick A, Freitag A, Lanz LM, Edelmann D, Suwala A, Breckwoldt MO, Harting I, Sahm F, Schlenk RF, Schmitt A, Schnell O, Hense J, Misch M, Krex D, Denk M, Walz J, Steinbach JP, von Deimling A, Schmitt M, Bunse T, Tabatabai G, Bendszus M, Poschke I, Wick W, Platten M (2026)
Publication Type: Journal article, Erratum
Publication year: 2026
Book Volume: 7
Pages Range: 1322-
Journal Issue: 8
DOI: 10.1038/s43018-026-01227-x
Correction to: Nature Cancerhttps://doi.org/10.1038/s43018-026-01199-y, published online 1 July 2026. In the version of the article initially published, in the Abstract, the sentence “The 8-year progression-free and overall survival (OS) rates were 0.42 months (confidence interval (CI): 0.24–0.59) and 0.66 months (CI: 0.46–0.79), respectively” should have read “The 8-year progression-free and overall survival (OS) rates were 0.42 (confidence interval (CI): 0.24–0.59) and 0.66 (CI: 0.46–0.79), respectively”. This correction has been made to the HTML and PDF versions of the article.
APA:
Bunse, L., Lindner, K., Wick, A., Freitag, A., Lanz, L.M., Edelmann, D.,... Platten, M. (2026). Author Correction: IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial (Nature Cancer, (2026), 10.1038/s43018-026-01199-y). Nature Cancer, 7(8), 1322-. https://doi.org/10.1038/s43018-026-01227-x
MLA:
Bunse, Lukas, et al. "Author Correction: IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial (Nature Cancer, (2026), 10.1038/s43018-026-01199-y)." Nature Cancer 7.8 (2026): 1322-.
BibTeX: Download